Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial

Felix Aberer\(^1\)*, Julia K Mader\(^1\), Julia Holzgruber\(^1\), Christian Trummer\(^1\), Verena Schwetz\(^1\), Marlene Pandis\(^1\), Peter N Pferschy\(^1\), Hildegard Greinix\(^2\), Norbert J Tripolt\(^1\), Thomas R Pieber\(^1,3,4\), Armin Zebisch\(^2\), Heinz Sill\(^2\), Albert Wolff\(^2,3\), Harald Sourij\(^1,3\)

\(^1\)Division of Endocrinology and Diabetology, \(^2\)Division of Hematology, Medical University of Graz, \(^3\)Center for Biomarker Research in Medicine (CBmed), and \(^4\)Health-Institute for Biomedicine and Health Sciences, Graz, Austria

**Keywords**
Decision support system, Feasibility trial, Steroid-induced hyperglycemia

*Correspondence*
Felix Aberer
Tel.: +43-316-385-86113
Fax: +43-316-385-13428
E-mail address: felix.aberer@medunigraz.at

J Diabetes Investig 2019; 10: 339–342
doi: 10.1111/jdi.12919

Clinical Trial Registry
European Clinical Trials Database
EudraCT 2014-004418-27

**INTRODUCTION**

Acute graft-versus-host disease (aGvHD) represents a frequent and potentially life-threatening complication occurring after allogeneic hematopoietic stem cell transplantation, and is characterized by an activation of donor T cells and release of proinflammatory mediators leading to host tissue apoptosis and necrosis affecting the skin, gastrointestinal tract, and liver\(^1\).

As first-line standard therapy, high-dose systemic glucocorticoids are recommended\(^3\), causing steroid-induced hyperglycemia (SIHG) in up to 80% of treated patients\(^3,4\).

We and others have recently identified SIHG as a potent and independent predictor for adverse outcome in patients with hematological malignancy\(^5\) and aGvHD\(^3,6\). Whether hyperglycemia represents a causal contributor to inferior outcome and an intensive glucose-lowering strategy might have an impact on the unfavorable prognosis remains unclear to date and needs to be further investigated in a randomized controlled trial.

During the past decades, automated decision support systems (DSS) recommending insulin dosing for hospitalized patients have been repeatedly tested and introduced into clinical practice\(^7,8\). Until present, such systems were exclusively tested and approved for the treatment of in-hospital (stress) hyperglycemia or type 2 diabetes mellitus, but not for patients with SIHG.

The aim of the present study was to evaluate the feasibility and safety using an automated DSS that incorporates an algorithm for basal–bolus insulin therapy (GlucoTab) in
hospitalized patients with aGVHD in a randomized controlled pilot trial as a prerequisite for a future multicenter outcome trial comparing intensive glucose control achieved by a DSS with conventional glucose control.

METHODS

Study design

We carried out a single center, randomized, controlled feasibility trial in 10 hospitalized aGVHD patients developing hyperglycemia (i.e., >2 fasting glucose values >140 mg/dL) after initiation of systemic glucocorticoid therapy. The study was approved by the local ethics committee (27-116 ex 14/15), registered (EudraCT Number: 2014-004418-27) and carried out in accordance with the declaration of Helsinki. All patients gave written consent before any study-related procedure.

Participants were randomly assigned using a web-based randomization tool (www.randomizer.at) to either insulin therapy suggested by GlucoTab (GT group) or to routine care according to local standards of care (SOC group). Follow-up duration was 6 months. If patients were readmitted to hospital during the follow-up period, they were treated according to the initial randomization result.

Despite the feasibility design and therefore small patient population, a randomized controlled trial design was chosen in order to oppose two different therapeutic approaches for the management of in-hospital hyperglycemia in patients with aGVHD. The primary aim of the study was to investigate the feasibility and safety of GlucoTab in the treatment of SIHG. Feasibility was assessed by the median glucose and percentage of plasma glucose (PG) values in the target range during systemic corticosteroid therapy. The main safety end-point was the number of hypoglycemic events.

GlucoTab®

GlucoTab (Decide, clinical software GmbH, Graz, Austria) is a DSS integrated in a mobile, handheld tablet computer suggesting subcutaneous basal–bolus insulin therapy provided by the incorporated standardized insulin dosing algorithm. This device has previously been tested and implemented in routine care (CE certified in 2013) in hospitalized non-critically ill patients with hyperglycemia with or without diabetes mellitus, and has been shown to be an effective tool for the establishment of safe and tight glycemic control. However, GlucoTab has not been used for the management of SIHG thus far. GlucoTab therapy requires four capillary glucose measurements per day (pre-meal, bedtime), and provides both bolus and basal insulin dosing suggestions. Once a patient is registered to be treated with the DSS, it recommends a first total daily insulin dose based on age, renal function and body mass index. During the course of treatment, the incorporated algorithm adapts its insulin suggestions to retrospective glycemic trends. The current version of the algorithm proposes basal and bolus insulin in a proportion of 50:50%, with the largest bolus of short-acting insulin in the morning. Dose suggestions can be overruled at any time by medical staff if deemed necessary or reasonable. In the present study, insulins aspart (NovoNordisk, Bagsvaerd, Denmark) and glargine (Sanofi-Aventis, Frankfurt am Main, Germany) were used. Further information characterizing the functionality of the algorithm and its efficacy and usability shown in previous studies are described elsewhere in detail.

For SOC, antihyperglycemic therapy was carried out at the discretion of the treating physician. According to the protocol, four daily glucose measurements were also requested in the SOC group throughout the trial.

Statistical analysis

For collection of baseline and aGVHD characteristics, we used descriptive statistics. Continuous data following a normal distribution are given as means with standard deviation, and variables with a skewed distribution are presented as medians with interquartile range (IQR). Categorical data are presented as percentages. Comparative analysis and significance testing were carried out using the Mann–Whitney U-test and χ²-test. Statistical analyses were carried out with SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). As the present study was a feasibility trial, no formal sample size calculation was carried out.

RESULTS

Patient characteristics

We included 10 patients (7 women) with aGVHD in the present randomized controlled feasibility trial. The mean age was 55 ± 13 versus 60 ± 4 years for GT and SOC, respectively. Table 1 shows further patient characteristics.

Primary outcome parameters

During in-hospital glucocorticoid therapy, a total of 364 (GT group) and 1,020 (SOC group) PG values were available. The median overall PG was significantly lower in the GT group (151 [IQR 123–192] vs 162 [IQR 138–193] mg/dL), as well as median fasting PG (131 [IQR 113–164] vs 152 [IQR 134–18] mg/dL and bedtime PG (159 [IQR 133–202] vs 188 [IQR 160–211] mg/dL; P < 0.001, respectively). PG values at lunchtime and in the evening showed no statistically significant difference. A total of 67.2% (GT) versus 60.2% (SOC) of all values were in the recommended target range (70–180 mg/dL; P < 0.001). Hypoglycemia (PG <70 mg/dL) appeared rarely in both groups with no statistical difference (P = 0.120). None of the hypoglycemic events was symptomatically noticed, required third party help or resulted in an adverse clinical outcome. Detailed information on primary outcome parameters is shown in Table 2.

Secondary outcome parameters

The mean total daily insulin dose was significantly higher in the GT (38 ± 29 IU) versus SOC group (11 ± 12 IU), and the
mean prednisolone dose was higher in the SOC group ($P < 0.001$). Table 3 shows further secondary outcome parameters.

**DISCUSSION**

Patients with aGVHD require high doses of steroids as first-line immunosuppressant therapy and consecutively frequently develop SIHG. Recent data showed that patients with aGVHD who develop SIHG face a substantially increased risk for non-relapse mortality, and this risk correlates with the extent of hyperglycemia.

Although glucose seems to be a prognostic marker, it remains unclear whether lowering hyperglycemia influences survival of these patients, which would need to be tested in an adequately powered outcome trial.

As a first step towards such a trial, we investigated the feasibility of carrying out a randomized controlled trial using a standardized DSS for basal–bolus insulin therapy in hospitalized patients with SIHG, which could serve as a tool for standardized, intensive glucose management in a future multicenter trial.

The present trial showed that median glucose levels were significantly lower in SIHG patients treated with a standardized DSS compared with usual care, without increasing the number of hypoglycemic events. In particular, median morning and bedtime glucose readings were lower in the DSS group, suggesting that the morning short-acting insulin dose will need to be increased further in the DSS algorithm optimized for steroid-induced hyperglycemia.

It is well known that patients who use short-acting or intermediate steroids are exposed to the development of a transient rise of hyperglycemia that persists for some hours. For this reason, future versions of the algorithm will have to be aware of

### Table 1 | Patient characteristics

|                                 | GT ($n = 5$) | SOC ($n = 5$) | $P$-value |
|--------------------------------|-------------|--------------|-----------|
| Sex (female)                   | 3/5         | 4/5          |           |
| Age (years)                    | $55.2 \pm 13.4$ | $60.2 \pm 3.66$ | 0.042     |
| BMI (kg/m$^2$)                 | 22.8 ± 4.6  | 24.5 ± 5.5   | 0.0516    |
| Underlying disease             |             |              |           |
| AML                            | 5           | 3            |           |
| ALL                            | 0           | 1            |           |
| aGVHD onset after SCT (days)   | 27 ± 19.9   | 26.6 ± 5.3   | 0.794     |
| GVHD affected organs           |             |              |           |
| Skin                           | 5           | 4            |           |
| Gastrointestinal tract         | 5           | 5            |           |
| Liver                          | 0           | 1            |           |
| Overall grading (Glucksberg)   | 2           | 2            |           |
| 3                              | 0           | 1            |           |
| 4                              | 3           | 3            |           |
| Donor type                     |             |              |           |
| Relative                       | 1 (HI)      | 2 (HI)       |           |
| Unrelated                      | 4           | 3            |           |
| Comorbidity index (HCT-CI)     |             |              |           |
| HCT-CI ≤1                      | 0           | 3            |           |
| HCT-CI >1                      | 5           | 2            |           |
| HLA match                      |             |              |           |
| Full match (12/12)             | 4           | 3            |           |
| Mismatch                       | 1           | 2            |           |

Age, body mass index (BMI) and acute graft-versus-host disease (aGVHD) onset are shown as the mean. ALL, acute lymphatic leukemia; AML, acute myeloid leukemia; GT, GlucoTab; HCT-CI, Hematopoietic Cell Transplantation-Comorbidity Index; HLA, human leukocyte antigen; SCT, stem cell transplantation; SOC, standard of care.

### Table 2 | Median glucose during different time-points, and percentage and amount of values during different glycemic ranges

| Group                        | GT ($n = 5$) | SOC ($n = 5$) | $P$-value |
|------------------------------|-------------|--------------|-----------|
|                              | PG (mg/dL) | IQR (95% CI) | n         | PG (mg/dL) | IQR (95% CI) | n     |
| Median glucose during time-points |             |              |           |           |              |       |
| Median PG morning            | 131         | 113–164      | 94        | 152       | 134–182      | 286   | <0.001 |
| Median PG lunch              | 148         | 120–185      | 92        | 157       | 134–182      | 279   | 0.421 |
| Median PG evening            | 179         | 178–223      | 96        | 191       | 157–230      | 265   | 0.201 |
| Median PG bedtime            | 159         | 132–202      | 82        | 188       | 160–211      | 190   | <0.001 |
| Median PG total              | 151         | 123–192      | 364       | 162       | 138–193      | 1020  | <0.001 |

| Percentage and amount of values during different glycemic ranges | GT ($n = 5$) | SOC ($n = 5$) | $P$-value |
|------------------------------------------------------------------|-------------|--------------|-----------|
| Hypoglycemia (<70 mg/dL)                                        | 0.8         | 3            | 0.2       | 2          | 0.120 |
| Target PG (70–180 mg/dL)                                        | 67.2        | 248          | 60.2      | 614        | 0.017 |
| Hyperglycemia (>180 mg/dL)                                      | 320         | 113          | 39.6      | 404        | 0.010 |
| Total                                                            | 100         | 364          | 100       | 1020       |      |

GT, GlucoTab; IQR, interquartile range; PG, plasma glucose; SOC, standard of care.
the time-point of steroid application, and also the type of steroid and its hyperglycemic potency must be taken into account in order to further improve the algorithm. These adjustments are indispensable before the system can be used in a trial investigating the effect of tight glycemic control on patient survival in aGVHD.

Apart from the hereby shown ability of GlucoTab to improve glycemia in patients with SIHG, we have to underline that we tested the device in a hospital unit that employs non-diabetologists. This emphasizes the potential benefit of GlucoTab to facilitate and standardize glycemic management for non-specified staff.

To our knowledge, this was the first trial testing a DSS for insulin therapy in patients with SIHG. The present results suggest that GlucoTab might be a suitable tool for the treatment of SIHG in patients suffering from aGVHD and other SIHG patients. Whether or not DSS-induced improved glycemia translates into a beneficial outcome in patients with aGVHD needs to be investigated in a larger outcome trial.

ACKNOWLEDGMENTS

We express our thanks to Bernhard Höll and the Decide Clinical Software GmBH for GlucoTab-related support. We also thank Beate Bougaropoulus for giving advice in terms of writing of this manuscript.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150–1163.

2. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet 2009; 373: 1550–1561.

3. Gebremedhin E, Behrendt CE, Nakamura R, et al. Severe hyperglycemia immediately after allogeneic hematopoietic stem-cell transplantation is predictive of acute graft-versus-host disease. Inflammation 2013; 36: 177–185.

4. Stauber MN, Aberer F, Oulhaj A, et al. Early hyperglycemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease. Biol Blood Marrow Transplant 2017; 23: 1186–1192.

5. Aberer F, Kremser S, Mader JK, et al. Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemia. Diabetes Metab 2017; 43: 560–562.

6. Pidala J, Kim J, Khafan-Dabaja MA, et al. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Transplant 2011; 17: 239–248.

7. Mader JK, Neubauer KM, Schaupp L, et al. Efficacy, usability and sequence of operations of a workflow-integrated algorithm for basal-bolus insulin therapy in hospitalized type 2 diabetes patients. Diabetes Obes Metab 2014; 16: 137–146.

8. Umpierrez GE, Smiley D, Hermayer K, et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care 2013; 36: 2169–2174.

9. Society AD. Austrian lipid consensus 2016. Central Eur J Med 2016; 128: 167–169.

10. Neubauer KM, Mader JK, Holl B, et al. Standardized glycemic management with a computerized workflow and decision support system for hospitalized patients with type 2 diabetes on different wards. Diabetes Technol Ther 2015; 17: 685–692.

Table 3 | Secondary outcome parameters

| Group            | GT (n = 5) | SD/IQR | SOC (n = 5) | SD/IQR | P-value |
|------------------|------------|--------|-------------|--------|---------|
| Mean total daily insulin dose (IU) | 38 | ±29 | 11 | ±12 | <0.001 |
| Mean prednisolone dose (mg) | 85 | ±53 | 98 | ±69 | <0.001 |
| Mean initial prednisolone dose (mg) | 113 | ±59 | 140 | ±53 | 0.458 |
| Median time of survival (days) | 105 | 39–161 | 136 | 86–165 | 0.458 |
| Median time of hospitalization (days) | 41 | 22–89 | 101 | 55–147 | 0.095 |
| Median percentage of hospitalization | 80 | 34–95 | 86 | 62–97 | 0.690 |
| Cause of death (n) | 4 | 4 | 4 | 4 | - |
| Infection (n) | 2 | 2 | 2 | 2 | - |
| Relapse (n) | 1 | 1 | 1 | 1 | - |
| aGVHD (n) | 1 | 1 | 1 | 1 | - |

Normally distributed parameters are given as the mean (standard deviation [SD]), non-normally distributed parameters are presented as the median (interquartile range [IQR]). aGVHD, acute graft-versus-host disease; GT, GlucoTab; IQR, interquartile range; SD, standard deviation; SOC, standard of care.